FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer (PaFLO)

Clinical Trial ID NCT01503372

Rank	Title	Journal	Year	PubWeight™‹?›
1	Capecitabine and oxaliplatin for advanced esophagogastric cancer.	N Engl J Med	2008	12.97
2	Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.	J Clin Oncol	2006	3.00
3	Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.	J Clin Oncol	2008	2.88
4	Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.	J Clin Oncol	2010	2.10
5	[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"].	Z Gastroenterol	2011	1.74
6	Current status of novel agents in advanced gastroesophageal adenocarcinoma.	J Gastrointest Oncol	2015	0.83
7	New advances in targeted gastric cancer treatment.	World J Gastroenterol	2016	0.81
8	Gastric cancer: The times they are a-changin'.	World J Gastrointest Oncol	2015	0.79
9	Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.	Int J Cancer	2021	0.75